Page last updated: 2024-08-24

glucose, (beta-d)-isomer and Pulmonary Arterial Hypertension

glucose, (beta-d)-isomer has been researched along with Pulmonary Arterial Hypertension in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's5 (100.00)2.80

Authors

AuthorsStudies
Fu, Q; He, J; Li, M; Peng, J; Tan, S; Tang, M; Tang, Y; Xie, W; Xu, X; Zhang, Q; Zhang, Y; Zheng, Z; Zhu, T1
Han, H; He, M; Hu, S; Kong, H; Tan, Q; Wang, H; Wang, J; Wang, Y; Wu, X; Xie, W; Xu, J; Yang, M; Yu, M1
Chang, R; Cui, B; Fan, Z; Hiram, R; Huang, C; Huang, H; Liu, T; Shi, S; Su, X; Tang, Y; Wu, G; Wu, J; Xiong, F; Yan, M; Zhang, W1
Al-Omran, M; Bhatt, DL; Chowdhury, B; Connelly, KA; Hess, DA; Kabir, MG; Luu, AZ; Luu, VZ; Mazer, CD; Pan, Y; Quan, A; Sabongui, S; Teoh, H; Verma, S1
Ding, Y; Huang, W; Kong, H; Liu, P; Peng, L; Tan, Q; Wang, H; Wang, J; Wang, Y; Xie, W; Yang, M; Yu, M; Zhou, H1

Trials

1 trial(s) available for glucose, (beta-d)-isomer and Pulmonary Arterial Hypertension

ArticleYear
Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling.
    Cardiovascular diabetology, 2022, 09-28, Volume: 21, Issue:1

    Topics: Animals; Arrhythmias, Cardiac; Benzhydryl Compounds; Calcium; Connexin 43; Disease Models, Animal; Fura-2; Glucose; Glucosides; Heart Failure; Monocrotaline; Pulmonary Arterial Hypertension; Rats; Sodium; Ventricular Dysfunction, Right; Ventricular Remodeling

2022

Other Studies

4 other study(ies) available for glucose, (beta-d)-isomer and Pulmonary Arterial Hypertension

ArticleYear
Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
    BMC pulmonary medicine, 2022, Apr-12, Volume: 22, Issue:1

    Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Glucosides; Humans; Hypertension, Pulmonary; Monocrotaline; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats; Sildenafil Citrate; Vascular Remodeling

2022
Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-κB pathways.
    International journal of medical sciences, 2022, Volume: 19, Issue:4

    Topics: Animals; Disease Models, Animal; Endothelial Cells; Glucosides; Hypertension, Pulmonary; MAP Kinase Kinase Kinases; Monocrotaline; Monoterpenes; NF-kappa B; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats

2022
The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
    Biochemical and biophysical research communications, 2020, 03-26, Volume: 524, Issue:1

    Topics: Animals; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Heart Ventricles; Hemodynamics; Humans; Hypertrophy, Right Ventricular; Lung; Male; Models, Animal; Monocrotaline; Mortality; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Sprague-Dawley; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors; Vascular Remodeling

2020
Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition.
    Drug design, development and therapy, 2020, Volume: 14

    Topics: Animals; Cells, Cultured; Chronic Disease; Disease Models, Animal; Endothelial Cells; Epithelial-Mesenchymal Transition; Glucosides; Humans; Hypoxia; Indoles; Injections, Subcutaneous; Male; Monoterpenes; Oxygen; Pulmonary Arterial Hypertension; Pyrroles; Rats; Rats, Sprague-Dawley

2020